Disrupting the main cardiac monitoring approach from surgery to the ICU

Disrupting the main cardiac monitoring approach from surgery to the ICU

31-10-18

Cardiaccs is on a mission to revolutionize the way that cardiac surgeons obtain insight about cardiac function and motion during and after an open-heart surgery. This insight is critical to timely detect surgical complications, such as myocardial infarction. Cardiaccs patented solution involves adding an accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days.

Cardiaccs and Innovayt started working together in 2015, when the technology was at early stage and with enough technical challenges to align well with the requirements of the EuroStars program. Innovayt consultants helped write the funded application that took the technology to the next step, being safe and effective for use in patients. As the EuroStars project approached its end, Cardiaccs and Innovayt decided to collaborate again to support the following steps to market, namely the collaborative maturation of the hardware and software elements and the multi-site clinical validation that is mandatory prior to market uptake of medical devices. The Fast Track to Innovation (FTI) program was the best match in EU programs, and Innovayt consultants again wrote the successful application that secured funding until 2021, when the innovative device is expected to reach operating rooms all over the world.